Bay Street News, January, 2019

Interim results anticipated in Q2 of 2019 SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (NASDAQ: ASMB), […]

Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) […]

– Expanding the Label for TIBSOVO®: Supplemental New Drug Application (sNDA) Submitted for TIBSOVO® as Monotherapy for Patients with Newly […]

MEDFORD, N.Y., Jan. 07, 2019 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on […]

The smart wearable harnessing the power of neurostimulation and AI to attack the chronic pain crisis LAS VEGAS, Jan. 07, […]

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing […]

Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of […]

LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA NDA submission targeted […]

SANTA CLARA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that pioneered the […]

Proof of concept that new class of lysin biologics has the potential to improve treatment outcomes in serious bacterial infections […]